ALK(SZ:002940) Zheng Quan Ri Bao·2025-10-24 23:38Core Viewpoint - The company emphasizes the accuracy and completeness of its financial disclosures and reports, ensuring accountability from its board and management [2][3][4]. Financial Data Summary - The third-quarter financial report has not been audited [10]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - As of the reporting period, the company holds 5,619,700 shares in its repurchase account, accounting for 2.79% of the total share capital [5]. - The company has engaged in various equity transactions, including a capital increase in Dongbao Technology amounting to 10 million yuan, raising its registered capital from 40 million to 50 million yuan [6][7]. - The company acquired a 4% stake in Jinhe Biology for 600,000 yuan, increasing its total ownership to 82.50% [7]. Legal Matters - The company faced a lawsuit from Jiangsu Yuehua Pharmaceutical Co., claiming 12.2322 million yuan in asset evaluation discrepancies. The court dismissed the claim, ordering the plaintiff to bear the litigation costs [6]. Strategic Collaborations - The company signed a strategic cooperation agreement with Aifei (Shanghai) Biopharmaceutical Technology Co., Ltd. and Shanghai Qinhuli Biopharmaceutical Technology Co., Ltd. regarding the ALK-N002 project, which has been approved by the shareholders' meeting [8].